Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common and lethal malignant tumours worldwide. Sorafenib (SOR) is one of the most effective single-drug systemic therapy against advanced HCC, but the identification of novel combination regimens for a continued improvement in overall sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Romito, Ilaria, Porru, Manuela, Braghini, Maria Rita, Pompili, Luca, Panera, Nadia, Crudele, Annalisa, Gnani, Daniela, De Stefanis, Cristiano, Scarsella, Marco, Pomella, Silvia, Levi Mortera, Stefano, de Billy, Emmanuel, Conti, Adrian Libenzio, Marzano, Valeria, Putignani, Lorenza, Vinciguerra, Manlio, Balsano, Clara, Pastore, Anna, Rota, Rossella, Tartaglia, Marco, Leonetti, Carlo, Alisi, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597092/
https://www.ncbi.nlm.nih.gov/pubmed/34784956
http://dx.doi.org/10.1186/s13046-021-02154-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597092/
https://www.ncbi.nlm.nih.gov/pubmed/34784956
http://dx.doi.org/10.1186/s13046-021-02154-8

Ejemplares similares